Fundamental Analysis Discussion Only (IXC Thread), page-14

Cheers. Those were along the same lines as my thoughts but thats a much better explanation of MOA.

Also important to note over the 3 month period exenatide actually showed a 37% reduction in MHD as opposed to 27% for MAB, even if MAB showed much more reductions as it went for longer.

And as you said it was for a patient population that is in ocular remission, which is significantly different to what presendin will be for, as a significant amount of the value will come from quickly lowering ICP for patients with visual issues